Related references
Note: Only part of the references are listed.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells
Li-Yuan Bai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma
Bevin Zimmerman et al.
LEUKEMIA RESEARCH (2011)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer
Yi-kang Shi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine
M-D Lai et al.
CANCER GENE THERAPY (2010)
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
Andelko Hrzenjak et al.
MOLECULAR CANCER (2010)
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
David M. Lucas et al.
PLOS ONE (2010)
A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer
Yen-An Tang et al.
PLOS ONE (2010)
Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo
Tatsuhito Nagumo et al.
ORAL ONCOLOGY (2009)
OSU-HDAC42, a Histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model
Aaron M. Sargeant et al.
CANCER RESEARCH (2008)
Generation and characterization of a preventive and therapeutic HPV DNA vaccine
Daejin Kim et al.
VACCINE (2008)
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
Bruce Huang et al.
VACCINE (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy
Jose A. Karam et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer
Samuel K. Kulp et al.
CLINICAL CANCER RESEARCH (2006)
Trichostatin-A enhances adaptive immune responses to DNA vaccination
Thiru Vanniasinkam et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone deacetylase inhibitors: discovery and development as anticancer agents
PA Marks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells
S Roy et al.
CELL DEATH AND DIFFERENTIATION (2005)
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
Q Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination
WF Cheng et al.
GENE THERAPY (2003)
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen
WF Cheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin
PA Wade
HUMAN MOLECULAR GENETICS (2001)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
TL Wang et al.
GENE THERAPY (2000)
Share Paper
